Loading...
Structural Basis for Designing Multiepitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation.
Srivastava, Sukrit Verma, Sonia Kamthania, Mohit Kaur, Rupinder Badyal, Ruchi Kiran Saxena, Ajay Kumar Shin, Ho-Joon Kolbe, Michael Pandey, Kailash C
Srivastava, Sukrit
Verma, Sonia
Kamthania, Mohit
Kaur, Rupinder
Badyal, Ruchi Kiran
Saxena, Ajay Kumar
Shin, Ho-Joon
Kolbe, Michael
Pandey, Kailash C
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2020-06-19
Submitted date
Files
Loading...
Open Access article
Adobe PDF, 1.53 MB
Other Titles
Abstract
Both designed MEVs are composed of CTL and HTL epitopes screened from 11 Open Reading Frame (ORF), structural and nonstructural proteins of the SARS-CoV-2 proteome. Both MEVs also carry potential B-cell linear and discontinuous epitopes as well as interferon gamma-inducing epitopes. To enhance the immune response of our vaccine design, truncated (residues 10-153) Onchocerca volvulus activation-associated secreted protein-1 was used as an adjuvant at the N termini of both MEVs. The tertiary models for both the designed MEVs were generated, refined, and further analyzed for stable molecular interaction with toll-like receptor 3. Codon-biased complementary DNA (cDNA) was generated for both MEVs and analyzed in silico for high level expression in a mammalian (human) host cell line.
Citation
JMIR Bioinform Biotech. 2020 Jun 19;1(1):e19371. doi: 10.2196/19371.
Publisher
DOI
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
2563-3570
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution 4.0 International